• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sangamo Therapeutics Inc.

    11/12/24 5:25:20 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGMO alert in real time by email
    S-8 1 ny20037443x2_s8.htm S-8

    As filed with the Securities and Exchange Commission on November 12, 2024

    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    SANGAMO THERAPEUTICS, INC.
    (Exact name of registrant as specified in its charter)
         
    Delaware
     
    68-0359556
    (State or other jurisdiction of
     incorporation or organization)
     
    (I.R.S. Employer
     Identification No.)
         
    501 Canal Blvd.
     Richmond, California
     
    94084
    (Address of Principal Executive Offices)
     
    (Zip Code)

    Amended and Restated Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan
    (Full title of the plan)

    Alexander D. Macrae
    President and Chief Executive Officer
    Sangamo Therapeutics, Inc.
    501 Canal Blvd.
    Richmond, California 94084
    (510) 970-6000
    (Name and address of agent for service) (telephone number, including area code, of agent for service)

    Copies to:


    Scott Willoughby
     Senior Vice President and General Counsel
     Sangamo Therapeutics, Inc.
     501 Canal Blvd.
     Richmond, California 94084
     (510) 970-6000
    Chadwick L. Mills
     Courtney M.W. Tygesson
     Cooley LLP
     3 Embarcadero Center, 20th Floor
     San Francisco, CA  94111
     (415) 693-2000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
                 
    Large accelerated filer
     
    ☐
     
    Accelerated filer
     
    ☒
    Non-accelerated filer
     
    ☐
     
    Smaller reporting company
     
    ☒
           
    Emerging growth company
     
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed by Sangamo Therapeutics, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 11,000,000 shares of the Registrant’s common stock, par value $0.01 per share (the “Common Stock”), to be issued pursuant to the Registrant’s Amended and Restated 2018 Equity Incentive Plan (the “2018 Plan”).  The Registrant previously registered (i) 19,131,725 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant’s registration statement on Form S-8 (File No. 333-225552) filed with the Commission on June 11, 2018 (the “2018 Form S-8”), (ii) 9,900,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant’s registration statement on Form S-8 (File No. 333-241033) filed with the Commission on August 5, 2020 (the “2020 Form S-8”), (iii) 7,900,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant’s registration statement on Form S-8 (File No. 333-269925) filed with the Commission on February 23, 2023 (the “2023 Form S-8”), and (iv) 10,000,000 shares of Common Stock that are or may become issuable under the 2018 Plan pursuant to the Registrant’s registration statement on Form S-8 (File No. 333-273805) filed with the Commission on August 8, 2023 (together with the 2018 Form S-8, the 2020 Form S-8, and the 2023 Form S-8, the “Prior Registration Statements”). This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated by reference herein.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.          Incorporation of Documents by Reference

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:


    •
    the Registrant’s annual report on Form 10-K for the year ended December 31, 2023, which was filed with the Commission on March 13, 2024;


    •
    the information specifically incorporated by reference into the Registrant’s annual report on Form 10-K for the year ended December 31, 2023 from the Registrant’s definitive proxy statement on Schedule 14A, which was filed with the Commission on April 19, 2024;


    •
    the Registrant’s quarterly reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, which were filed with the Commission on May 9, 2024, August 6, 2024 and November 12, 2024, respectively;


    •
    the Registrant’s current reports on Form 8-K, which were filed with the Commission on January 19, 2024, February 6, 2024, March 25, 2024, April 30, 2024, June 5, 2024 and July 24, 2024; and


    •
    the description of the Common Stock contained in the Registrant’s registration statement on Form 8-A, which was filed with the Commission on March 31, 2000, including all amendments and reports filed for the purpose of updating such description, including Exhibit 4.1 of the Registrant’s annual report on Form 10-K for the year ended December 31, 2023.

    All reports and other documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.


    Item 8.
    Exhibits
         
    Exhibit
    Number
     
    Description
       
    4.1
     
    Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K filed June 2, 2023).
    4.2
     
    Certificate of Amendment of the Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 5, 2024).
    4.3
     
    Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed December 19, 2022).
    5.1
     
    Opinion of Cooley LLP.
    23.1
     
    Consent of Independent Registered Public Accounting Firm.
    23.2
     
    Consent of Cooley LLP is contained in Exhibit 5.1 to this Registration Statement.
    24.1
     
    Power of Attorney is contained on the signature page hereto.
    99.1
     
    Amended and Restated Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed June 5, 2024).
    107
     
    Filing fee table.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Richmond, State of California, on November 12, 2024.
         
    SANGAMO THERAPEUTICS, INC.
       
    By:
     
    /s/ Alexander D. Macrae
       
    Alexander D. Macrae, M.B., Ch.B., Ph.D.
       
    President and Chief Executive Officer
    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Alexander D. Macrae, Prathyusha Duraibabu and Scott Willoughby, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution and resubstitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     Signature    Ttle    Date
             
    /s/ Alexander D. Macrae
     
    President, Chief Executive Officer and Director
     
    November 12, 2024
    Alexander D. Macrae, M.B., Ch.B., Ph.D.
     
    (Principal Executive Officer)
     

     
     
    /s/ Prathyusha Duraibabu
      Senior Vice President and Chief Financial Officer  
    November 12, 2024
    Prathyusha Duraibabu
     
    (Principal Financial and Accounting Officer)
     

     
     
    /s/ H. Stewart Parker
     
    Director and Chairman of the Board
     
    November 12, 2024
    H. Stewart Parker
     
     

     
     
    /s/ Courtney Beers
      Director  
    November 12, 2024
    Courtney Beers, Ph.D.
     
     

     
     
    /s/ Robert F. Carey
      Director  
    November 12, 2024
    Robert F. Carey
     
     

     
     
    /s/ Kenneth J. Hillan
      Director  
    November 12, 2024
    Kenneth J. Hillan, M.B., Ch.B.
     
     

     
     
    /s/ Margaret A. Horn
      Director  
    November 12, 2024
    Margaret A. Horn
     
     

     
     
    /s/ John H. Markels
      Director  
    November 12, 2024
    John H. Markels, Ph.D.
     
     

     
     
    /s/ James R. Meyers
      Director  
    November 12, 2024
    James R. Meyers
     
     

     
     
    /s/ Karen L. Smith
      Director  
    November 12, 2024
    Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.
     
     

     
     



    Get the next $SGMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGMO

    DatePrice TargetRatingAnalyst
    12/13/2024$7.00Hold → Buy
    Truist
    12/10/2024$10.00Buy
    H.C. Wainwright
    11/3/2023$6.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    4/28/2023$5.00 → $1.50Neutral → Underperform
    BofA Securities
    2/27/2023$16.00Neutral → Outperform
    Wedbush
    1/6/2023$8.00 → $5.00Buy → Neutral
    BofA Securities
    6/13/2022$5.00Neutral
    Wedbush
    More analyst ratings

    $SGMO
    SEC Filings

    See more
    • Sangamo Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      5/6/25 4:03:49 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Sangamo Therapeutics Inc.

      10-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      3/17/25 4:05:16 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

      3/17/25 4:01:39 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      11/12/24 4:53:35 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      11/4/24 1:54:32 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

      SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

      8/16/24 6:40:25 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, GEN. COUNSEL & SECRETARY Willoughby Scott B. covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 782,976 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:10:48 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 779,937 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:09:40 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 126,950 shares, decreasing direct ownership by 5% to 2,325,898 units (SEC Form 4)

      4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

      4/24/25 4:08:28 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Leadership Updates

    Live Leadership Updates

    See more
    • Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm

      5/16/23 8:00:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

      CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio

      11/22/21 7:00:00 AM ET
      $ORGO
      $PACB
      $SGMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa

      5/24/21 4:15:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe

      5/6/25 4:35:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

      All dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920. According to preliminary analysis, mean estimated glomerular filtration rate (eGFR) slope at 52-weeks continued to remain positive. Productive Type B Chemistry, Manufacturing and Controls (CMC) meeting with FDA provided clear CMC pathway to planned Biologics License Application (BLA) submission. Pivotal data readout expected by end of second quarter of 2025. Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced important derisking events in the pathway to a planned BLA submission for isaralgagen

      5/6/25 8:30:00 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

      One abstract accepted as platform presentation in prestigious Presidential Symposium, demonstrating potent combination of epigenetic regulation and capsid delivery technology in treating prion disease in animal models Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the 28th ASGCT Annual Meeting being held May 13-17, 2025, in-person in New Orleans, LA and in a virtual format. Presentations will highlight the progression of Sangamo's neurology pipeline, including advances in zinc finger epigenetic regulation, the latest innovations in capsid

      4/28/25 4:31:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sangamo Therapeutics upgraded by Truist with a new price target

      Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00

      12/13/24 8:18:20 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Sangamo Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00

      12/10/24 11:58:57 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Sangamo Therapeutics from Outperform to Sector Perform and set a new price target of $2.00 from $6.00 previously

      11/3/23 7:45:03 AM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SGMO
    Financials

    Live finance-specific insights

    See more
    • Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe

      5/6/25 4:35:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 2024 to develop novel genomic medicines for neurodegenerative diseases and a capsid license agreement with Astellas in December 2024 to deliver genomic medicines for up to five neurological disease targets. Raised over $100 million in funding in 2024 through non-dilutive license fees and milestone payments, as well as equity financing. Investigational new drug (IND) application cleared by U.S. Food and Drug Administrati

      3/17/25 4:01:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

      Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on Monday, March 17, 2025. The company also plans to participate in an upcoming investor conference. Fourth Quarter and Full Year 2024 Earnings Results The company will hold its fourth quarter and full year 2024 results conference call at 4:30 p.m. Eastern on Monday, March 17, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this

      3/6/25 4:05:00 PM ET
      $SGMO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care